Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950123-11-094853
Filing Date
2011-11-03
Accepted
2011-11-03 16:19:56
Documents
12
Period of Report
2011-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q c23793e10vq.htm 10-Q 412369
2 EXHIBIT 10.1 c23793exv10w1.htm EX-10.1 73301
3 EXHIBIT 10.2 c23793exv10w2.htm EX-10.2 27342
4 EXHIBIT 31.1 c23793exv31w1.htm EX-31.1 5842
5 EXHIBIT 31.2 c23793exv31w2.htm EX-31.2 6103
6 EXHIBIT 32.1 c23793exv32w1.htm EX-32.1 2887
7 EXHIBIT 32.2 c23793exv32w2.htm EX-32.2 2910
  Complete submission text file 0000950123-11-094853.txt   1644162

Data Files

Seq Description Document Type Size
8 EX-101 INSTANCE DOCUMENT ogxi-20110930.xml EX-101.INS 173420
9 EX-101 SCHEMA DOCUMENT ogxi-20110930.xsd EX-101.SCH 9525
10 EX-101 CALCULATION LINKBASE DOCUMENT ogxi-20110930_cal.xml EX-101.CAL 28062
11 EX-101 LABELS LINKBASE DOCUMENT ogxi-20110930_lab.xml EX-101.LAB 95051
12 EX-101 PRESENTATION LINKBASE DOCUMENT ogxi-20110930_pre.xml EX-101.PRE 60001
Mailing Address 1522 217TH PLACE S.E. BOTHELL WA 98021
Business Address 1522 217TH PLACE S.E. BOTHELL WA 98021 4254879500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 111178007
SIC: 2835 In Vitro & In Vivo Diagnostic Substances